ESMO Press Releases

If you require further information regarding any of the press releases listed below, please do not hesitate to contact us (select 'Press & Media').

Filter

Date Title Topic
10 Sep 2017 ESMO 2017 Press Release: Ramucirumab plus Docetaxel Improves Progression-free survival in Urothelial Cancer Genitourinary cancers
10 Sep 2017 ESMO 2017 Press Release: Mature Results Favour Pembrolizumab As Second-line Treatment For Bladder Cancer Genitourinary cancers
10 Sep 2017 ESMO 2017 Press Release: Study Shows ESMO Magnitude of Benefit Scale Can Be Used to Grade Orphan Drugs
10 Sep 2017 ESMO 2017 Press Release: Study Confirms Chemoradiation is Best Treatment for Locally Advanced Cervical Cancer Gynaecologic malignancies
10 Sep 2017 ESMO 2017 Press Release: Cancer Patients Struggle with Key Aspects of Clinical Trial Methodology
09 Sep 2017 ESMO 2017 Media Alert: Hot Topic at ESMO 2017: Session Focuses on Adjuvant Chemotherapy Duration in Colon Cancer
09 Sep 2017 ESMO 2017 Press Release: Durvalumab Improves Progression-free Survival in Stage III Lung Cancer Lung and other thoracic tumours
09 Sep 2017 ESMO 2017 Press Release: Patients Feel Psycho-social Impact of Chemo More Acutely Than Physical Side Effects
09 Sep 2017 ESMO 2017 Press Release: Osimertinib Improves Progression-free Survival in Patients with EGFR Mutated Lung Cancer Lung and other thoracic tumours
09 Sep 2017 ESMO 2017 Press Release: “Triggers”: a New Tool to Assess Cancer Patients’ Palliative Needs Palliative and supportive care
09 Sep 2017 ESMO 2017 Press Release: Study Identifies Factors that Limit Work Ability of Young Adult Cancer Survivors
08 Sep 2017 ESMO 2017 Press Release: DNA Sequencing Could Open Up New Drug Indications for Patients with Rare Cancers Translational research
08 Sep 2017 ESMO 2017 Press Release: LORELEI: Taselisib Boosts Breast Tumor Shrinkage Breast cancer
08 Sep 2017 ESMO 2017 Press Release: New Data Confirms Superiority of Docetaxel Based Triplet Therapy in Gastric Cancer Gastrointestinal cancers
08 Sep 2017 ESMO 2017 Press Release: Pembrolizumab: Promising Response Rate in Pretreated Metastatic Gastric Cancer Gastrointestinal cancers